Developer docs
API playgroundTry for free, no card

Search company profiles

Blue Goose Capital

Full company profile

uuid000o3sp

Namestring
Blue Goose Capital
Legal namestring
Blue Goose Capital
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Blue Goose Capital is a privately-held venture capital firm headquartered at 48 Plympton Rd, Sudbury, Massachusetts, specializing in equity investments in US biotechnology companies at the Series A stage and forward. The firm operates through two fund vehicles: the original Blue Goose 1 and the successor Blue Goose Capital 2 fund, which was announced in March 2024. Its disclosed investment focus spans antibody-drug conjugates, oncology resistance research, non-invasive blood cell monitoring, neurodegeneration therapeutics, respiratory digital health, vision technology, rehabilitation exoskeletons, DNA testing, and brain health — covering both therapeutics and medical device/digital health sub-sectors within biotech.

The firm generates returns through capital gains realized on portfolio company exits, IPOs, or secondary sales of equity. Deal sourcing is conducted via co-investor syndicates and direct network-based outreach rather than broad marketing. Blue Goose Capital does not develop proprietary technology products; its core product is capital allocation and sector expertise. Portfolio companies include Mythic Therapeutics (participated in $103M Series B), Therini Bio ($36M Series A), Aluna (~$19M Series B), and Leuko ($5M Series A), alongside other holdings such as WIVI Vision, ABLE, ADNTRO, AtG, and Newmanbrain. The firm maintains limited public-facing marketing and operates with a discreet, relationship-driven go-to-market motion.

The firm's value proposition rests on sector-specialized capital deployment in US biotech, providing growth capital to fund clinical advancement (including first-in-human studies), pipeline expansion, and regulatory milestones. Geographic scope is restricted to the United States. Ownership structure, fund size, team composition, and management fees are not publicly disclosed in available source material, constituting data gaps for deeper diligence.

Short descriptiontext

Blue Goose Capital is a privately-held venture capital firm based in Sudbury, Massachusetts that makes Series A and Series B equity investments in US biotechnology companies, operating two fund vehicles (Blue Goose 1 and Blue Goose 2).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital funds, biotech investments, series a financing, series b financing, equity investments
Industry1 code
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code1 code
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns / Capital Gains
TypeTransaction Fee
Description

Blue Goose Capital generates returns through equity investments in biotech startups. The fund makes Series A and Series B investments and realizes returns through exits, IPOs, or secondary sales of portfolio company equity.

bluegoosecap.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Blue Goose 1
Description

First fund vehicle of Blue Goose Capital, focused on biotech investments

bluegoosecap.com
+1 more record
Core offering1 text field

Blue Goose Capital is a venture capital firm that makes direct equity investments in US-based biotechnology companies at the Series A and Series B stages. The firm operates two fund vehicles (Blue Goose 1 and Blue Goose Capital 2, the latter announced in March 2024) and deploys specialized capital into startups developing novel therapeutics, medical devices, and digital health technologies. Returns are generated through exits, IPOs, or secondary sales of portfolio company equity.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Blue Goose Capital is a venture capital firm focused on biotech investments in the US, operating two fund vehicles (Blue Goose 1 and Blue Goose 2). The firm does not appear to offer technology products or services; rather, it operates as an investment fund making Series A and forward-stage investments in biotechnology companies.

Product and service2 records
1Blue Goose 1 Fund
CategoryVenture Capital Fund
2Blue Goose Capital 2 Fund
CategoryVenture Capital Fund
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeGTM or Marketing Partner
Description

WIVI Vision, a Blue Goose Capital portfolio company, entered into a partnership agreement with General Optica to include WIVI Vision's technology in several of their optical shops. This represents a go-to-market partnership for the portfolio company's technology distribution.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Section 32 is a venture capital fund focused on biotech, techbio, and healthcare at early and growth stages. Directly comparable to Blue Goose given biotech specialization and early-stage Series A/B orientation.

TypeDirect peer
Description

Flagship Pioneering creates and funds early-stage biotech platforms, with deep specialization in therapeutics and life sciences. Comparable to Blue Goose for sector focus but typically operates earlier at the company-creation stage.

TypeDirect peer
Description

ARCH Venture Partners invests in early-stage biotech and technology companies, often co-founding and seeding life sciences ventures. Comparable to Blue Goose for early-stage biotech focus and syndicate participation.

TypeBroad incumbent
Description

a16z operates a dedicated bio/health fund alongside broad tech investing, providing a much larger platform than Blue Goose. Comparable as a sector-specialist investor in biotech but operates at significantly greater scale and brand.

TypeDirect peer
Description

OrbiMed is a healthcare-dedicated investment firm managing funds across venture, growth, and credit in biotech and medtech. Comparable to Blue Goose for biotech focus but operates at a meaningfully larger AUM scale.

TypeDirect peer
Description

Lux Capital invests in science-driven and frontier-technology companies including biotech and life sciences at early stages. Comparable to Blue Goose for early-stage investing in science-heavy categories.

TypeDirect peer
Description

Third Rock Ventures launches and invests in early-stage biotech companies focused on transformative therapies. Directly comparable to Blue Goose for biotech-only sector focus and company-building approach.

TypeDirect peer
Description

5AM Ventures is an early-stage venture capital firm focused on life sciences and biotech, investing in Series A rounds. Comparable to Blue Goose in fund-stage focus and biotech sector specialization.

TypeDirect peer
Description

Atlas Venture is a leading early-stage biotech-focused venture capital firm that builds and invests in therapeutic companies at the seed/Series A stage. Directly comparable to Blue Goose given its biotech specialization and early-stage investment focus.

TypeDirect peer
Description

RA Capital is a healthcare and biotech-focused investment firm with dedicated early-stage life sciences strategies. Comparable to Blue Goose for its sector specialization and early-to-mid-stage biotech investment activity.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Blue Goose Capital

Venture Capitalbluegoosecap.com

Blue Goose Capital is a privately-held venture capital firm based in Sudbury, Massachusetts that makes Series A and Series B equity investments in US biotechnology companies, operating two fund vehicles (Blue Goose 1 and Blue Goose 2).

What Blue Goose Capital does

Blue Goose Capital is a privately-held venture capital firm headquartered at 48 Plympton Rd, Sudbury, Massachusetts, specializing in equity investments in US biotechnology companies at the Series A stage and forward. The firm operates through two fund vehicles: the original Blue Goose 1 and the successor Blue Goose Capital 2 fund, which was announced in March 2024. Its disclosed investment focus spans antibody-drug conjugates, oncology resistance research, non-invasive blood cell monitoring, neurodegeneration therapeutics, respiratory digital health, vision technology, rehabilitation exoskeletons, DNA testing, and brain health — covering both therapeutics and medical device/digital health sub-sectors within biotech.

The firm generates returns through capital gains realized on portfolio company exits, IPOs, or secondary sales of equity. Deal sourcing is conducted via co-investor syndicates and direct network-based outreach rather than broad marketing. Blue Goose Capital does not develop proprietary technology products; its core product is capital allocation and sector expertise. Portfolio companies include Mythic Therapeutics (participated in $103M Series B), Therini Bio ($36M Series A), Aluna (~$19M Series B), and Leuko ($5M Series A), alongside other holdings such as WIVI Vision, ABLE, ADNTRO, AtG, and Newmanbrain. The firm maintains limited public-facing marketing and operates with a discreet, relationship-driven go-to-market motion.

The firm's value proposition rests on sector-specialized capital deployment in US biotech, providing growth capital to fund clinical advancement (including first-in-human studies), pipeline expansion, and regulatory milestones. Geographic scope is restricted to the United States. Ownership structure, fund size, team composition, and management fees are not publicly disclosed in available source material, constituting data gaps for deeper diligence.

Blue Goose Capital firmographics

Firmographics
Name
Blue Goose Capital
Legal name
Blue Goose Capital
Website
https://bluegoosecap.com
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
Blue Goose Capital is a privately-held venture capital firm based in Sudbury, Massachusetts that makes Series A and Series B equity investments in US biotechnology companies, operating two fund vehicles (Blue Goose 1 and Blue Goose 2).
Ownership category
akta.pro rank

Blue Goose Capital industry classification

Industry
Product category
Venture Capital
NAICS
Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Venture capital funds
  • Biotech investments
  • Series a financing
  • Series b financing
  • Equity investments

Where Blue Goose Capital is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Blue Goose Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations

Revenue model

  1. Investment Returns / Capital Gains: Blue Goose Capital generates returns through equity investments in biotech startups. The fund makes Series A and Series B investments and realizes returns through exits, IPOs, or secondary sales of portfolio company equity.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Blue Goose Capital product offering

Product offering

Core offering

Blue Goose Capital is a venture capital firm that makes direct equity investments in US-based biotechnology companies at the Series A and Series B stages. The firm operates two fund vehicles (Blue Goose 1 and Blue Goose Capital 2, the latter announced in March 2024) and deploys specialized capital into startups developing novel therapeutics, medical devices, and digital health technologies. Returns are generated through exits, IPOs, or secondary sales of portfolio company equity.

Product overview

Blue Goose Capital is a venture capital firm focused on biotech investments in the US, operating two fund vehicles (Blue Goose 1 and Blue Goose 2). The firm does not appear to offer technology products or services; rather, it operates as an investment fund making Series A and forward-stage investments in biotechnology companies.

Differentiator

Problem solved

Functional benefit

Brands

  • Blue Goose 1: First fund vehicle of Blue Goose Capital, focused on biotech investments
  • Blue Goose 2

Products and services

  • Blue Goose 1 Fund
  • Blue Goose Capital 2 Fund

Companies that use Blue Goose Capital

Customer profile

Named customers8 records

Segments1 record

Ideal customer profiles1 record

Blue Goose Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Blue Goose Capital partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • General OpticacoreGTM or Marketing PartnerWIVI Vision, a Blue Goose Capital portfolio company, entered into a partnership agreement with General Optica to include WIVI Vision's technology in several of their optical shops. This represents a go-to-market partnership for the portfolio company's technology distribution.

Scale indicators4 records

Recent moves6 records

Expansion highlights3 records

Blue Goose Capital competitors and assessment

Company assessment

Direct peers

  • Section 32: Section 32 is a venture capital fund focused on biotech, techbio, and healthcare at early and growth stages. Directly comparable to Blue Goose given biotech specialization and early-stage Series A/B orientation.
  • Flagship Pioneering: Flagship Pioneering creates and funds early-stage biotech platforms, with deep specialization in therapeutics and life sciences. Comparable to Blue Goose for sector focus but typically operates earlier at the company-creation stage.
  • ARCH Venture Partners: ARCH Venture Partners invests in early-stage biotech and technology companies, often co-founding and seeding life sciences ventures. Comparable to Blue Goose for early-stage biotech focus and syndicate participation.
  • OrbiMed Advisors: OrbiMed is a healthcare-dedicated investment firm managing funds across venture, growth, and credit in biotech and medtech. Comparable to Blue Goose for biotech focus but operates at a meaningfully larger AUM scale.
  • Lux Capital: Lux Capital invests in science-driven and frontier-technology companies including biotech and life sciences at early stages. Comparable to Blue Goose for early-stage investing in science-heavy categories.
  • Third Rock Ventures: Third Rock Ventures launches and invests in early-stage biotech companies focused on transformative therapies. Directly comparable to Blue Goose for biotech-only sector focus and company-building approach.
  • 5AM Ventures: 5AM Ventures is an early-stage venture capital firm focused on life sciences and biotech, investing in Series A rounds. Comparable to Blue Goose in fund-stage focus and biotech sector specialization.
  • Atlas Venture: Atlas Venture is a leading early-stage biotech-focused venture capital firm that builds and invests in therapeutic companies at the seed/Series A stage. Directly comparable to Blue Goose given its biotech specialization and early-stage investment focus.
  • RA Capital Management: RA Capital is a healthcare and biotech-focused investment firm with dedicated early-stage life sciences strategies. Comparable to Blue Goose for its sector specialization and early-to-mid-stage biotech investment activity.

Broad incumbents

  • Andreessen Horowitz (a16z Bio): a16z operates a dedicated bio/health fund alongside broad tech investing, providing a much larger platform than Blue Goose. Comparable as a sector-specialist investor in biotech but operates at significantly greater scale and brand.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Blue Goose Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Blue Goose Capital leadership team

Management profile

Number of profiles

Blue Goose Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Blue Goose Capital M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blue Goose Capital

What does Blue Goose Capital do?

Blue Goose Capital is a venture capital firm that makes direct equity investments in US-based biotechnology companies at the Series A and Series B stages. The firm operates two fund vehicles (Blue Goose 1 and Blue Goose Capital 2, the latter announced in March 2024) and deploys specialized capital into startups developing novel therapeutics, medical devices, and digital health technologies. Returns are generated through exits, IPOs, or secondary sales of portfolio company equity.

Is Blue Goose Capital a public or private company?

Blue Goose Capital is a private company. It is classified as unknown and is currently operating.

When was Blue Goose Capital founded?

Blue Goose Capital was founded in -1. It employs 1 to 10 people.

Where is Blue Goose Capital based?

Blue Goose Capital is headquartered in Cambridge, United States, in the North America region.

How does Blue Goose Capital make money?

One revenue line is on record: investment Returns / Capital Gains.

Who are Blue Goose Capital's main competitors?

Direct peers on record are Section 32, Flagship Pioneering, ARCH Venture Partners, OrbiMed Advisors, Lux Capital, Third Rock Ventures, 5AM Ventures, Atlas Venture and RA Capital Management. Andreessen Horowitz (a16z Bio) is listed as a broad incumbent.

Does Blue Goose Capital have an API?

No public API is recorded for Blue Goose Capital.

What industry is Blue Goose Capital in?

Blue Goose Capital's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals